Abg Realty

Drug giant Pfizer to add jobs in Mass.

By Robert Weisman, Globe Staff Drug giant Pfizer Inc. today said it will add about 350 jobs in the Boston area and look for a new site to house a pair of research operations it will move from southeastern Connecticut. The news came as Pfizer, the world’s largest pharmaceutical company, unveiled a broad restructuring plan […]

Read more

Dunkin’ will celebrate Feb. with chocolate donuts

February is “chocolate lovers month,” according to Dunkin’ Donuts, and it plans to celebrate the culinary festivities with “a new line of yeast raised chocolate donuts” to augment its offerings of chocolate cake style donuts. In a press release, the Canton-based coffee-and-baked-goods chain said its “renowned culinary team has worked for several years to create […]

Read more

Landmark Center is sold for $530.5m

The Abbey Group said today that it has sold Landmark Center, an office and retail complex near Fenway Park, for $530.5 million. The buyer is a joint venture between JP Morgan Investment Management Inc. and Samuels & Associates, said the Abbey Group, a Boston real estate company. Tenants at Lanmark Center include Blue Cross Blue […]

Read more

CHA completes major reconfiguration including Somerville Hospital

Somerville — The move next week of Cambridge Health Alliance’s Human Resources Department into CHA’s Somerville Hospital Campus completes a major system-wide reconfiguration project that began nearly two years ago in the wake of state budget cuts that threatened the public healthcare system’s viability. “Two years ago there were concerns and even suggestions that we […]

Read more

Getting Around Gets Easier

Big Dig mandates are bringing transit to the inner-ring suburbs. Public transit in the Boston area owes a giant debt to the Big Dig, the multibillion-dollar project that essentially buried the Central Artery expressway and in the process created a new roadway network. It’s the new highways, tunnels, and a high-style bridge that catch the […]

Read more

H3 Biomedicine launches with $200M from Eisai

Eisai Inc. launched on Thursday a wholly owned research and development subsidiary in Cambridge called H3 Biomedicine Inc. that will focus on personalized cancer medicines based on cancer genetics and chemistry advances. Eisai, the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., has pledged up to $200 million in research funding, plus more for clinical […]

Read more

Compare